Kemble George 4
4 · Sagimet Biosciences Inc. · Filed Jun 10, 2025
Insider Transaction Report
Form 4
Kemble George
DirectorExecutive Chairman
Transactions
- Award
Stock Option (Right to Buy)
2025-06-09+32,250→ 32,250 totalExercise: $5.33Exp: 2035-06-08→ Series A Common Stock (32,250 underlying)
Footnotes (1)
- [F1]The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 9, 2025, subject to the Reporting Person's continued service on each such vesting date.